Maze Therapeutics, Inc. (MAZE) — SEC Filings
Maze Therapeutics, Inc. (MAZE) — 13 SEC filings. Latest: 10-K (Mar 25, 2026). Includes 4 8-K, 3 10-Q, 2 10-K.
View Maze Therapeutics, Inc. on SEC EDGAR
Overview
Maze Therapeutics, Inc. (MAZE) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-K filed on Mar 25, 2026: Maze Therapeutics, Inc. (MAZE) is a clinical-stage biopharmaceutical company focused on kidney and metabolic diseases. For the fiscal year ended December 31, 2025, the company reported positive topline clinical proof of concept data in March 2026 for its lead program, MZE829, an APOL1 inhibitor for
Sentiment Summary
Across 13 filings, the sentiment breakdown is: 1 bearish, 8 neutral, 4 mixed. The dominant filing sentiment for Maze Therapeutics, Inc. is neutral.
Filing Type Overview
Maze Therapeutics, Inc. (MAZE) has filed 2 10-K, 4 8-K, 3 10-Q, 2 S-1, 2 S-1/A with the SEC between Jan 2025 to Mar 2026.
Filings by Year
Recent SEC Filings (13)
| Date | Form | Description | Risk |
|---|---|---|---|
| Mar 25, 2026 | 10-K | Maze Therapeutics' Lead Drug Shows Promise in Kidney Disease Trial | high |
| Mar 25, 2026 | 8-K | Maze Therapeutics Files 8-K on Operations, Officer Changes | |
| Nov 6, 2025 | 10-Q | MAZE Swings to $96.5M Loss Amid Zero License Revenue, R&D Spikes | high |
| Oct 17, 2025 | S-1 | Maze Therapeutics S-1 Signals Resale of $150M Private Placement Shares | high |
| Oct 6, 2025 | 8-K | Maze Therapeutics Announces Board and Executive Changes | medium |
| Sep 11, 2025 | 8-K | Maze Therapeutics Files 8-K: Material Agreement, Equity Sales | medium |
| Sep 2, 2025 | 8-K | Maze Therapeutics Announces Board and Compensation Changes | medium |
| Aug 12, 2025 | 10-Q | Maze Therapeutics Swings to Loss Amid IPO, R&D Spend | high |
| May 14, 2025 | 10-Q | Maze Therapeutics Files Q1 2025 10-Q | medium |
| Mar 31, 2025 | 10-K | 10-K Filing | |
| Jan 30, 2025 | S-1/A | Maze Therapeutics Files IPO Amendment | medium |
| Jan 27, 2025 | S-1/A | Maze Therapeutics Files S-1/A for IPO | medium |
| Jan 7, 2025 | S-1 | Maze Therapeutics Files S-1 for Public Offering | medium |
Risk Profile
Risk Assessment: Of MAZE's 11 recent filings, 4 were flagged as high-risk, 7 as medium-risk, and 0 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | Not disclosed |
| Net Income | Not disclosed |
| EPS | Not disclosed |
| Debt-to-Equity | Not disclosed |
| Cash Position | Not disclosed |
| Operating Margin | Not disclosed |
| Total Assets | Not disclosed |
| Total Debt | Not disclosed |
Key Executives
- Jason Coloma, Ph.D.
- Effie Toshav, Esq.
- Amanda Rose, Esq.
- Chelsea Anderson, Esq.
- Courtney Phillips
- Ryan Mitteness, Esq.
- Chelsea Ande
Industry Context
Maze Therapeutics operates in the highly competitive biopharmaceutical sector, focusing on the unmet needs in kidney and metabolic diseases. The industry is characterized by significant R&D investment, lengthy development cycles, and stringent regulatory oversight. Recent trends show increasing interest in genetically targeted therapies and precision medicine approaches, which aligns with Maze's strategy for AMKD and potentially PKU.
Top Tags
Biotechnology (4) · biotech (4) · Clinical Stage (3) · ipo (3) · Kidney Disease (2) · Metabolic Disorders (2) · Drug Development (2) · Net Loss (2) · IPO (2) · Private Placement (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Aggregate market value of common stock held by non-affiliates | $443.9 million | as of June 30, 2025, indicating current market capitalization for non-insiders |
| Closing price per share | $12.27 | on June 30, 2025, used to calculate market value |
| Mean reduction in uACR for MZE829 | 35.6% | at week 12 in evaluable AMKD patients in Phase 2 trial, indicating efficacy |
| Mean uACR reduction for MZE829 | 61.8% | in a subset of FSGS patients, highlighting strong efficacy in a specific AMKD subgroup |
| Healthy adult volunteers enrolled in MZE829 Phase 1 trial | 111 | demonstrating initial safety and pharmacokinetics |
| Patients enrolled in MZE829 Phase 2 trial | 15 | for safety and tolerability analysis |
| Patients evaluable for efficacy in MZE829 Phase 2 trial | 12 | providing the basis for the positive topline data |
| Healthy adult volunteers enrolled in MZE782 Phase 1 trial | 112 | demonstrating initial safety and pharmacokinetic profile |
| Shares of common stock outstanding | 49,708,658 | as of March 20, 2026 |
| Planned initiation of two Phase 2 trials for MZE782 | 2026 | indicating upcoming clinical milestones |
| Net Loss | $96.552M | for the nine months ended September 30, 2025, compared to $81.810M net income in 2024 |
| License Revenue | $0 | for the nine months ended September 30, 2025, down from $167.500M in 2024 |
| Research and Development Expenses | $80.878M | for the nine months ended September 30, 2025, up from $61.280M in 2024 |
| Cash and Cash Equivalents | $316.773M | as of September 30, 2025, up from $196.812M at December 31, 2024 |
| Accumulated Deficit | $454.979M | as of September 30, 2025, widened from $358.427M at December 31, 2024 |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Maze Therapeutics, Inc. (MAZE)?
Maze Therapeutics, Inc. has 13 recent SEC filings from Jan 2025 to Mar 2026, including 4 8-K, 3 10-Q, 2 10-K. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of MAZE filings?
Across 13 filings, the sentiment breakdown is: 1 bearish, 8 neutral, 4 mixed. The dominant sentiment is neutral.
Where can I find Maze Therapeutics, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Maze Therapeutics, Inc. (MAZE) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Maze Therapeutics, Inc.?
Key financial highlights from Maze Therapeutics, Inc.'s most recent 10-K include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for MAZE?
The investment thesis for MAZE includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Maze Therapeutics, Inc.?
Key executives identified across Maze Therapeutics, Inc.'s filings include Jason Coloma, Ph.D., Effie Toshav, Esq., Amanda Rose, Esq., Chelsea Anderson, Esq., Courtney Phillips and 2 others.
What are the main risk factors for Maze Therapeutics, Inc. stock?
Of MAZE's 11 assessed filings, 4 were flagged high-risk, 7 medium-risk, and 0 low-risk.
What are recent predictions and forward guidance from Maze Therapeutics, Inc.?
Forward guidance and predictions for Maze Therapeutics, Inc. are extracted from SEC filings as they are enriched.